Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Equity Average (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Equity Average for 16 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Equity Average fell 32.14% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 32.14% year-over-year, with the annual reading at $1.3 billion for FY2025, 17.38% down from the prior year.
  • Equity Average hit $1.0 billion in Q4 2025 for Integra Lifesciences Holdings, roughly flat from $1.0 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.8 billion in Q4 2022 to a low of $1.0 billion in Q3 2025.
  • Historically, Equity Average has averaged $1.5 billion across 5 years, with a median of $1.6 billion in 2023.
  • Biggest five-year swings in Equity Average: increased 16.73% in 2021 and later tumbled 32.14% in 2025.
  • Year by year, Equity Average stood at $1.7 billion in 2021, then rose by 6.4% to $1.8 billion in 2022, then fell by 10.25% to $1.6 billion in 2023, then fell by 3.16% to $1.5 billion in 2024, then crashed by 32.14% to $1.0 billion in 2025.
  • Business Quant data shows Equity Average for IART at $1.0 billion in Q4 2025, $1.0 billion in Q3 2025, and $1.3 billion in Q2 2025.